Andere talen vTv Therapeutics Inc.

Aandelen

VTVT

US9183852048

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
17,66 ^USD	+3,82%		-6,21%	+53,57%

24/06	VTv Therapeutics kondigt de screening aan van de eerste patiënt in CATT1-pivotaal onderzoek naar cadisegliatine voor type 1-diabetes	CI
09/05	VTv Therapeutics Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

VTv Therapeutics Announces Screening of First Patient in Trial of Cadisegliatin for Type 1 Diabetes	24/06
VTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes	24/06
VTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes	24/06
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING	28/05
VTv Therapeutics: Q1 Earnings Snapshot	09/05
VTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update	09/05
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
VTv Therapeutics : 2024 Notice of Annual Meeting and Proxy Statement	30/04
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT	19/03
VTv Therapeutics Inc. Announces Board Changes	14/03
VTv Therapeutics: Q4 Earnings Snapshot	13/03
VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update	13/03
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	13/03
VTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference	04/03
VTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes	04/03
VTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes	04/03
VTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference	01/03
Top Midday Gainers	28/02
VTv Therapeutics Inc. Announces Board Changes	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen vTv Therapeutics Inc.

Aandelen

VTVT

US9183852048

Andere talen

Filters